Long Term Arrhythmia Risk and Cardiovascular Events in Hematopoietic Stem Cell Transplant (ARCHER)

  • End date
    Apr 17, 2023
  • participants needed
  • sponsor
    Abramson Cancer Center of the University of Pennsylvania
Updated on 17 June 2022
heart failure
vascular disease
atrial flutter
recurrent atrial fibrillation


The purpose of this study is to better understand the following aims:

  1. Aim 1: To evaluate the rate of recurrent Atrial Fibrillation (AF)/Atrial Flutter (AFL) in hematopoietic stem call transplant (HCST) patients with incident AF/AFL identified during the initial 30 days of the transplant
  2. Aim 2: To evaluate incident episodes of 1) stroke/TIA; 2) other thromboembolic events (not stroke/TIA); 3) Heart failure events; 4) Ischemic heart events
  3. Aim 3: To evaluate overall implantation safety in this population


We propose a registry study in hematopoietic stem cell transplant (HSCT) patients with incident atrial fibrillation/atrial flutter (AF/AFL) during the initial 30 days of transplant who will be implanted with the Medtronic Reveal Linq Implantable Cardiac Monitor (ICM) within 90 days of HSCT. We will evaluate the rate of recurrent AF/AFL as well as incident episodes of major cardiovascular events and the safety of ICM implantation in this population.

Condition Hematopoietic Stem Cell Transplant, Atrial Fibrillation, Atrial Flutter
Treatment HSCT Patients
Clinical Study IdentifierNCT04118530
SponsorAbramson Cancer Center of the University of Pennsylvania
Last Modified on17 June 2022


Yes No Not Sure

Inclusion Criteria

Age ≥18
Recovery of platelets to >50,000 within 90 days of incident atrial fibrillation (AF) diagnosis
Discharge from the incident stem cell transplant (SCT) hospitalization
Normal sinus rhythm at the time of consent

Exclusion Criteria

Prior history of atrial fibrillation (AF) or atrial flutter
Platelets <50,000 after 90 days post transplantation
Continued SCT hospitalization at 90 days
Inability to receive anticoagulation
AF or other arrhythmia at the time of consent
Current use of a class IC or III antiarrhythmic medication
Inability to provide informed consent/significant cognitive impairment
Expected survival less than one year
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note